Synaptodendritic injury with HIV-Tat protein: What is the therapeutic target?

Experimental Neurology

Volumn 251, Issue , 2014, Pages 112-114

  Natha, Avindra ^a   Steinerb, Joseph ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA1 INTEGRIN; ALPHAVBETA5 INTEGRIN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CXCR4; CYSTEINE; DARUNAVIR; DIPEPTIDYL PEPTIDASE IV; HIV GAG POL POLYPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEOHEPARAN SULFATE; RECEPTOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VIRUS PROTEIN; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; AMNESIA; ARTICLE; ASTROCYTE; CD4 LYMPHOCYTE COUNT; DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LEARNING DISORDER; NERVE CELL LESION; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SYNAPTODENDRITIC INJURY; VIRUS LOAD; VIRUS REPLICATION;

EID: 84888865292     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.11.004     Document Type: Note

References (26)

1. Archibald S.L., Masliah E., Fennema-Notestine C., Marcotte T.D., Ellis R.J., McCutchan J.A., Heaton R.K., Grant I., Mallory M., Miller A., et al. Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch. Neurol. 2004, 61:369-376.
2. Bruce-Keller A.J., Chauhan A., Dimayuga F.O., Gee J., Keller J.N., Nath A. Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J. Neurosci. 2003, 23:8417-8422.
3. Carey A.N., Sypek E.I., Singh H.D., Kaufman M.J., McLaughlin J.P. Expression of HIV-Tat protein is associated with learning and memory deficits in the mouse. Behav. Brain Res. 2012, 229:48-56.
4. Carey A.N., Liu X., Mintzopoulos D., Paris J.J., Muschamp J.W., McLaughlin J.P., Kaufman M.J. Conditional Tat protein expression in the GT-tg bigenic mouse brain induces gray matter density reductions. Prog. Neuro-psychopharm. Biol. Psychiatry 2013, 43:49-54.
5. Eugenin E.A., King J.E., Nath A., Calderon T.M., Zukin R.S., Bennett M.V., Berman J.W. HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:3438-3443.
6. Fitting S., Ignatowska-Jankowska B.M., Bull C., Skoff R.P., Lichtman A.H., Wise L.E., Fox M.A., Su J., Medina A.E., Krahe T.E., et al. Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 Tat transgenic mice. Biol. Psychiatry 2013, 73:443-453.
7. Gelman B.B., Lisinicchia J.G., Chen T., Johnson K.M., Jennings K., Freeman D.H., Soukup V.M. Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J. Neuroimmune Pharm. 2012, 7:686-700.
8. Ghezzi S., Noonan D.M., Aluigi M.G., Vallanti G., Cota M., Benelli R., Morini M., Reeves J.D., Vicenzi E., Poli G., et al. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem. Biophys. Res. Commun. 2000, 270:992-996.
9. Heaton R.K., Franklin D.R., Ellis R.J., McCutchan J.A., Letendre S.L., Leblanc S., Corkran S.H., Duarte N.A., Clifford D.B., Woods S.P., et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J. Neurovirol. 2011, 17:3-16.
10. Jeang K.T., Xiao H., Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J. Biol. Chem. 1999, 274:28837-28840.
11. Johnson T.P., Patel K., Johnson K.R., Maric D., Calabresi P.A., Hasbun R., Nath A. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:13588-13593.
12. Kranick S.M., Nath A. Neurologic complications of HIV-1 infection and its treatment in the era of antiretroviral therapy. Continuum 2012, 18:1319-1337.
13. Li W., Huang Y., Reid R., Steiner J., Malpica-Llanos T., Darden T.A., Shankar S.K., Mahadevan A., Satishchandra P., Nath A. NMDA receptor activation by HIV-Tat protein is clade dependent. J. Neurosci. 2008, 28:12190-12198.
14. Liu Y., Jones M., Hingtgen C.M., Bu G., Laribee N., Tanzi R.E., Moir R.D., Nath A., He J.J. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 2000, 6:1380-1387.
15. Lu S.M., Tremblay M.E., King I.L., Qi J., Reynolds H.M., Marker D.F., Varrone J.J., Majewska A.K., Dewhurst S., Gelbard H.A. HIV-1 Tat-induced microgliosis and synaptic damage via interactions between peripheral and central myeloid cells. PLoS One 2011, 6:e23915.
16. Marban C., Su T., Ferrari R., Li B., Vatakis D., Pellegrini M., Zack J.A., Rohr O., Kurdistani S.K. Genome-wide binding map of the HIV-1 Tat protein to the human genome. PLoS One 2011, 6:e26894.
17. Masliah E., Achim C.L., Ge N., DeTeresa R., Terry R.D., Wiley C.A. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann. Neurol. 1992, 32:321-329.
18. McArthur J.C., Steiner J., Sacktor N., Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann. Neurol. 2010, 67:699-714.
19. Nath A., Psooy K., Martin C., Knudsen B., Magnuson D.S., Haughey N., Geiger J.D. Identification of a human immunodeficiency virus type 1 Tat epitope that is neuroexcitatory and neurotoxic. J. Virol. 1996, 70:1475-1480.
20. Noonan D., Albini A. From the outside in: extracellular activities of HIV Tat. Adv. Pharmacol. 2000, 48:229-250.
21. Peng F., Yao H., Akturk H.K., Buch S. Platelet-derived growth factor CC-mediated neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta. PLoS One 2012, 7:e47572.
22. Perry S.W., Barbieri J., Tong N., Polesskaya O., Pudasaini S., Stout A., Lu R., Kiebala M., Maggirwar S.B., Gelbard H.A. Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax. J. Neurosci. 2010, 30:14153-14164.
23. Shin A.H., Thayer S.A. Human immunodeficiency virus-1 protein Tat induces excitotoxic loss of presynaptic terminals in hippocampal cultures. Mol. Cell. Neurosci. 2013, 54:22-29.
24. Theodore S., Cass W.A., Dwoskin L.P., Maragos W.F. HIV-1 protein Tat inhibits vesicular monoamine transporter-2 activity in rat striatum. Synapse 2012, 66:755-757.
25. Turchan J., Sacktor N., Wojna V., Conant K., Nath A. Neuroprotective therapy for HIV dementia. Curr. HIV Res. 2003, 1:373-383.
26. Tyagi M., Rusnati M., Presta M., Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276:3254-3261.